天康生物(002100.SZ):控股股東增持公司股份計劃完成
格隆匯11月3日丨天康生物(002100.SZ)公佈,公司控股股東新疆生產建設兵團國有資產經營有限責任公司(以下簡稱"兵團國資公司")自首次增持之日(2022年10月28日)起6個月內,計劃以自有資金增持公司股份,擬增持金額不低於人民幣5,000萬元,不超過人民幣10,000萬元,本次增持未設置價格區間。
截至公吿披露日,本次增持股份計劃期限屆滿,兵團國資公司已按計劃完成本次增持股份計劃。實施期限內,兵團國資公司通過深圳證券交易所交易系統以集中競價交易方式累計增持公司股份10,651,738股,佔公司總股本的0.79%,增持金額為88,034,832.01元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.